Key Points
- Neil Kumar, BridgeBio Pharma's CEO, sold 30,011 shares on December 15 at an average price of $74.64 for $2.24M, leaving him with 228,776 shares (~$17.08M) and reducing his stake by 11.6%.
- The December sale is part of a recent string of insider sales by Kumar (Oct–Dec) totaling about 176,167 shares for roughly $11.66M across five transactions.
- Despite the insider selling, analysts remain largely positive—21 Buys vs. 1 Sell with a consensus target of $76.25—and BBIO trades near its 52-week high ($76.51) with a market cap of about $14.59B.
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 30,011 shares of the firm's stock in a transaction on Monday, December 15th. The shares were sold at an average price of $74.64, for a total transaction of $2,240,021.04. Following the completion of the transaction, the chief executive officer directly owned 228,776 shares of the company's stock, valued at approximately $17,075,840.64. This trade represents a 11.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Neil Kumar also recently made the following trade(s):
- On Thursday, December 4th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $74.40, for a total transaction of $2,976,000.00.
- On Thursday, November 20th, Neil Kumar sold 26,156 shares of BridgeBio Pharma stock. The stock was sold at an average price of $65.84, for a total transaction of $1,722,111.04.
- On Thursday, November 6th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $63.15, for a total value of $2,526,000.00.
- On Wednesday, October 8th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $54.78, for a total value of $2,191,200.00.
BridgeBio Pharma Stock Performance
NASDAQ:BBIO opened at $75.69 on Wednesday. BridgeBio Pharma, Inc. has a 52-week low of $25.34 and a 52-week high of $76.51. The company has a market cap of $14.59 billion, a P/E ratio of -18.11 and a beta of 1.26. The stock's 50-day simple moving average is $64.92 and its 200 day simple moving average is $53.41.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). The company had revenue of $120.70 million during the quarter, compared to analysts' expectations of $107.71 million. The business's revenue was up 4318.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.86) earnings per share. As a group, equities analysts predict that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on the company. UBS Group increased their price objective on BridgeBio Pharma from $72.00 to $82.00 and gave the company a "buy" rating in a report on Friday, September 12th. Cowen reaffirmed a "positive" rating on shares of BridgeBio Pharma in a research report on Thursday, October 30th. Raymond James Financial reissued an "outperform" rating and issued a $71.00 price objective (up previously from $69.00) on shares of BridgeBio Pharma in a research report on Thursday, October 30th. Wells Fargo & Company raised their target price on shares of BridgeBio Pharma from $76.00 to $84.00 and gave the company an "overweight" rating in a research note on Tuesday, November 11th. Finally, Cantor Fitzgerald boosted their price target on BridgeBio Pharma from $100.00 to $110.00 and gave the stock an "overweight" rating in a research report on Thursday, October 30th. Twenty-one analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $76.25.
View Our Latest Analysis on BBIO
Institutional Investors Weigh In On BridgeBio Pharma
A number of large investors have recently modified their holdings of the business. WINTON GROUP Ltd acquired a new stake in BridgeBio Pharma in the second quarter valued at approximately $3,856,000. Moss Adams Wealth Advisors LLC lifted its stake in shares of BridgeBio Pharma by 49.2% in the 2nd quarter. Moss Adams Wealth Advisors LLC now owns 24,172 shares of the company's stock valued at $1,044,000 after acquiring an additional 7,970 shares during the last quarter. Baird Financial Group Inc. bought a new position in shares of BridgeBio Pharma in the 1st quarter valued at $1,429,000. Bosun Asset Management LLC boosted its holdings in shares of BridgeBio Pharma by 119.7% during the 2nd quarter. Bosun Asset Management LLC now owns 26,154 shares of the company's stock valued at $1,129,000 after acquiring an additional 14,250 shares in the last quarter. Finally, Intech Investment Management LLC grew its position in BridgeBio Pharma by 12.0% during the 1st quarter. Intech Investment Management LLC now owns 73,524 shares of the company's stock worth $2,542,000 after acquiring an additional 7,877 shares during the last quarter. Institutional investors and hedge funds own 99.85% of the company's stock.
About BridgeBio Pharma
(
Get Free Report)
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
